The Company has already shown that several of its nanoviricide drug candidates were more than 25 times (2,500%) superior to a three-drug HAART cocktail in a standard SCID-hu Thy/Liv mouse model study of HIV-I infection. In particular, treatment with only 150mg/kg nanoviricides, as opposed to 4,200 mg/kg HAART drug cocktail (i.e. 28 times greater dosage of HAART cocktail) resulted in viral load decrease that was equal to or better than HAART, and double-positive CD4+/CD8+ T cell counts that were equal to or better than HAART. In addition, the nanoviricides were superior to the HAART cocktail in all parameters evaluated.

Significantly, the nanoviricide treatment was given only during the first week in this six-week anti-HIV study, whereas HAART treatment was continued daily. These anti-HIV nanoviricide drug candidates will be further evaluated in cell culture studies at Southern Research Institute, advancing towards our goal of filing pre-IND and later IND applications to the FDA.

Strategy to Maximize the Likelihood of Success in Drug Development

We have a large number of highly active backup drug candidates for each of the viruses we are working on, unlike most other companies that have one or very few active drug candidates, said Anil R. Diwan, PhD, President of the Company, explaining, Nanoviricides technology enables us to develop novel, effective drug candidates in a very short time frame.

We maximize the likelihood of having a successful drug by advancing several candidates through the pipeline for each of our programs, said Eugene Seymour, MD, MPH, CEO of the Company.

Source: NanoViricides, Inc.